OncoMatch

OncoMatch/Clinical Trials/NCT06603402

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

Is NCT06603402 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for esophageal squamous cell carcinoma (escc).

Phase 2RecruitingSichuan UniversityNCT06603402Data as of May 2026

The aim of this clinical trial is to evaluate whether low-dose involved-field radiotherapy combined with immunochemotherapy can reduce treatment-related adverse effects, enhance progression-free survival (PFS), and improve overall survival (OS) in patients with locally advanced, unresectable esophageal squamous cell carcinoma. The key questions this study seeks to address are: * Can low-dose involved-field radiotherapy combined with immunochemotherapy reduce treatment-related adverse effects? * Does this combined approach improve PFS and OS in these patients? Participants in the study will: * Undergo an endoscopy at West China Hospital to confirm their diagnosis. * Receive a treatment regimen that includes low-dose radiotherapy at 45.0 Gy in 1.8 Gy per fraction over 25 fractions, alongside immunochemotherapy, with three cycles of chemotherapy administered every 3 weeks. * After completing the full treatment regimen, participants will undergo regular follow-up visits and monitoring by healthcare professionals.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage III

Patients with locally advanced, unresectable ESCC who have received radical treatment (radical chemoradiotherapy or radical radiochemotherapy), including: Cervical esophagus involvement, T4 stage, supraclavicular lymph node metastasis, or inability to tolerate or refusal of surgery due to personal reasons; Failure of neoadjuvant or conversion therapy; Unresectable local recurrence after surgery (with measurable target lesions)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: radical chemoradiotherapy

have received radical treatment (radical chemoradiotherapy or radical radiochemotherapy)

Lab requirements

Blood counts

Normal function of major organs

Kidney function

Normal function of major organs

Liver function

Normal function of major organs

Cardiac function

Normal function of major organs

Normal function of major organs

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify